Breaking News

AstraZeneca Enters Agreement to Lower U.S. Drug Prices

AstraZeneca to invest $50 billion in manufacturing and R&D to support domestic sourcing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca

AstraZeneca has entered an agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for Americans while investing in America’s biopharmaceutical innovation. AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the company voluntarily met all requests set out in the President’s July 31st letter. The Company agrees to a range of measures which will enable Americans to access medicines at prices that a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters